NeoGenomics, Inc. (NEO) — Fair Value Analysis
Base-case fair value (P50): $17.56 · Current price: $13.90 · Verdict: Undervalued
The Verdict on NEO
NEOGENOMICS INC (NEO) is currently Fairly Valued according to our Monte Carlo simulations. With NEO trading at $13.90, our P50 median fair value estimate stands at $17.56. This suggests a potential +26.4% upside to our central estimate, indicating that the market price is largely aligned with the company's intrinsic value, as derived from thousands of forward-looking scenarios. The "Fairly Valued" verdict for NEO aligns with a scenario where the company's current valuation reflects its average operational and financial health relative to its sector, preventing a strong bullish or bearish signal based solely on this metric.
How NEO stacks up against peers
NEO's quality tier is assessed as average when comparing its operational and financial health against its sector. This average quality tier suggests that while NEO is not a standout performer, it also doesn't present significant red flags compared to its peers. The current trading price of $13.90 and the P50 fair value of $17.56 reflect this positioning. An average quality tier combined with a +26.4% potential points to a company that is priced appropriately for its fundamental characteristics within its competitive landscape. Investors should consider how this average quality tier impacts their risk-adjusted return expectations for an investment at $13.90.
What this means for investors
For investors considering NEOGENOMICS INC (NEO), the assessment of Fairly Valued at $13.90 with a P50 median fair value of $17.56 and +26.4% potential suggests a balanced risk-reward profile. The average quality tier indicates that while there's no immediate undervaluation to exploit, nor significant overvaluation to avoid, the company's fundamentals are robust enough to support its current pricing. Investors seeking substantial upside might look for tickers with higher implied upside, but NEO's current pricing reflects its foundational strength. A downside scenario, while always possible, is factored into the distribution, and a bull case scenario could see the company surpass $17.56. To understand the full bear/bull distribution and track NEO's fair value as new fundamentals are released, sign up for a free FairCurve account.
Frequently Asked Questions
Is NEO overvalued or undervalued right now?
Based on Monte Carlo simulations, NEOGENOMICS INC (NEO) is currently considered fairly valued. Our median fair value (P50) is $17.56, compared to its current trading price of $13.90.
What is the bear case and bull case for NEO?
The full Monte Carlo distribution, including bear (P10) and bull (P90) target prices, along with the probability of achieving upside, is available with a free FairCurve account. We do not provide specific dollar values for these scenarios here.
How does FairCurve calculate NEO's fair value?
FairCurve calculates NEO's fair value using proprietary Monte Carlo simulations that model thousands of forward scenarios based on historical data and current market conditions. This provides a robust probabilistic valuation without relying on single-point estimates.
How can I track NEO's fair value as it changes?
To continuously monitor NEO's fair value, add it to your free FairCurve watchlist. You'll receive daily fair-value updates and instant re-valuations when new earnings or significant fundamental data are released.